The Conversation (0)
Imagin Medical (CSE: IME), as a follow-up to the announcement dated November 29, released additional information concerning the research study using the i/Blue Imaging System being conducted at the University of Rochester Medical Center. As quoted in the press release: The purpose of the study is to validate previous bench-testing results that showed the i/Blue Imaging …
Imagin Medical (CSE: IME), as a follow-up to the announcement dated November 29, released additional information concerning the research study using the i/Blue Imaging System being conducted at the University of Rochester Medical Center.
As quoted in the press release:
The purpose of the study is to validate previous bench-testing results that showed the i/Blue Imaging System technology will enable physicians to “see” the cancer in less than 15 minutes vs. the full hour required by today’s technology, as well as blend the white and florescence images into one, placing the cancer in context within the bladder.
